ERBB2 and hydrops fetalis: The baseline characteristics of patients with HF and non-HF events were similar, except for the proportion of HER2-positive patients (73.3% vs. 39.1%, p = 0.005), LVEF before chemotherapy (65.3 ± 6.1% vs. 68.7 ± 6.5%, p = 0.046), LVEDD before chemotherapy (48.7 ± 4.9 mm vs. 43.8 ± 4.6 mm, p = 0.003), and trastuzumab use (60.0% vs. 17.6%, p < 0.001) (Table 1).